Zevra Therapeutics CEO Neil F. McFarlane disposes of 20,000 common shares for USD 224,948
Zevra Therapeutics President and CEO Neil F. McFarlane acquired 50,000 common shares on Oct. 10, 2026 via RSU vesting. McFarlane sold 20,000 common shares on Oct. 12, 2026 at a weighted average price of $11.2474. Directly held common shares totaled 417,225 following the sale. Disclaimer: This news brief was created by